Accenture has agreed to acquire Enterprise System Partners (ESP), a consulting and manufacturing services provider for the life sciences industry headquartered in Cork, Ireland, and serving clients around the globe. Upon close, ESP will join Accenture Industry X.0, which helps clients master the digital reinvention of industry, strengthening Accenture’s capabilities to transform manufacturing for pharmaceutical, biotech and medical device clients globally.⨠â¨ESP has long-standing industry experience in planning and implementing manufacturing solutions, with niche expertise in manufacturing execution systems (MES) and serialization. MES digitally track and document the production process, providing the groundwork for more automated and analytics-driven manufacturing and supply chains. Serialization allows life science companies to digitally track each saleable unit from the packaging line all the way to the patient. ESP will be the latest of several acquisitions Accenture has made recently to expand Accenture Industry X.0 in Europe and North America, including embedded software company Pillar Technology (US), hardware engineering firm Mindtribe (US), and strategic design consultancy designaffairs.⨠Alastair Blair, country managing director for Accenture in Ireland, said: “The planned acquisition of ESP underscores our commitment to one of Ireland’s most important and growing industries – life sciences. We continue to invest in Ireland to grow our talent and increase our capabilities to help our clients apply the very latest digital technologies and drive innovation, further strengthening the position of Ireland as a leader in this industry.”⨠In February 2017, Accenture opened The Dock, Accenture’s global innovation hub, which now employees over 300 people in Dublin, and in February 2018, Accenture acquired Rothco, a full service creative agency in Dublin with more than 170 employees.
ESP brings a team of professionals with manufacturing, process, and IT knowledge.
The Weight-Loss Gold Rush: Legal and Regulatory Implications
July 11th 2024Jim Shehan, chair of the FDA Regulatory practice, Lowenstein Sandler, discusses how the FDA and other regulators likely to respond to the increased public interest and potential off-label use of GLP-1 drugs, what needs to be done for GLP-1s to be covered, advice for investors and financiers considering entering the weight-loss medication market and more.
Healthcare Marketing Strategies for Reaching Diverse Audiences
May 14th 2024Amanda Powers-Han, Chief Marketing Officer, Greater Than One, and Pharmaceutical Executive Editorial Advisory Board member, discusses how improved DE&I in healthcare marketing strategies can not only reach diverse audiences more effectively but also contribute to improved patient care outcomes, challenges faced in crafting culturally sensitive messages, and much more.